Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Clinical trial NCT05374590 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05374590
- Sponsor
- argenx
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-18
- Primary completion
- 2029-09-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.